AbbVie (ABBV) Stock Overview
A research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 4/6 |
Rewards
Risk Analysis
+ 1 more risk
ABBV Community Fair Values
Create NarrativeSee what 443 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
AbbVie Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$211.32 |
| 52 Week High | US$244.81 |
| 52 Week Low | US$176.57 |
| Beta | 0.36 |
| 1 Month Change | -2.84% |
| 3 Month Change | -5.24% |
| 1 Year Change | 9.30% |
| 3 Year Change | 43.40% |
| 5 Year Change | 82.05% |
| Change since IPO | 503.77% |
Recent News & Updates
AbbVie: Balancing Potential Acquisition Impact With Positive Q1 2026 Earnings
Apr 30
ABBV: Future Returns Will Rely On Immunology Expansion And Operating Leverage Execution
Analysts made a small upward adjustment to AbbVie’s fair value estimate to about $249. The modest change reflects a mix of slightly higher assumed discount rates and future P/E multiples, alongside recent shifts in Street price targets, including both raises and trims from firms such as Piper Sandler, Guggenheim, Cantor Fitzgerald, Evercore ISI, Citi and UBS, as well as fresh bullish initiations from Canaccord, RBC Capital and Barclays.Recent updates
AbbVie: Balancing Potential Acquisition Impact With Positive Q1 2026 Earnings
Apr 30ABBV: Future Returns Will Rely On Immunology Expansion And Operating Leverage Execution
Analysts made a small upward adjustment to AbbVie’s fair value estimate to about $249. The modest change reflects a mix of slightly higher assumed discount rates and future P/E multiples, alongside recent shifts in Street price targets, including both raises and trims from firms such as Piper Sandler, Guggenheim, Cantor Fitzgerald, Evercore ISI, Citi and UBS, as well as fresh bullish initiations from Canaccord, RBC Capital and Barclays.ABBV: Future Returns Will Hinge On Immunology Encore And Operating Leverage Execution
Analysts have made a modest upward adjustment to AbbVie’s price target, reflecting updated views on its immunology pipeline potential, operating leverage, and the ongoing debate about whether recent share underperformance and selloffs adequately reflect competitive risks. Analyst Commentary Recent research on AbbVie highlights a split view, with some analysts focusing on the upside from the immunology pipeline and operating leverage, while others point to valuation and competitive questions after a period of share underperformance.ABBV: Future Returns Will Hinge On Immunology Encore Outweighing Competitive Concerns
Narrative Update The analyst price target for AbbVie has been adjusted slightly higher to reflect a fair value move to about $249. Analysts point to early stage indication expansion, operating leverage potential, and ongoing immunology pipeline developments, even as some firms flag emerging competition and a more balanced risk and reward profile.ABBV: Future Returns Will Depend On Immunology Encore And Deal Optionality Uncertainty
The analyst price target for AbbVie edges higher to align with our fair value shift from $248.29 to $248.86, as analysts highlight ongoing indication expansion in immunology, potential operating leverage, and multiple expansion drivers, even as some firms note emerging competition and a more balanced risk and reward profile. Analyst Commentary Recent research on AbbVie reflects a split view, with some analysts pointing to upside tied to immunology growth and pipeline execution, while others flag competition risk and a more balanced risk and reward profile at current levels.
AbbVie Inc. (ABBV): The Immunology Powerhouse – Successfully Navigating the Post-Humira Transition
AbbVie (ABBV) has entered 2026 as a masterclass in pharmaceutical "lifecycle management," having effectively neutralized the long-feared "patent cliff" of its flagship drug, Humira. As of the February 27, 2026 close, the stock is trading at $232.03 , following a robust 3.3% single-day gain that capped off a volatile but ultimately bullish month.ABBV: Future Returns Will Rely On Immunology Encore And Evolving Deal Optionality
Our updated AbbVie narrative reflects a modest price target increase to about $248 per share, as analysts point to potential operating leverage, room for P/E multiple expansion, and a pipeline of proof-of-concept and immunology programs that could support slightly higher revenue growth assumptions, even as margin expectations are trimmed. Analyst Commentary Recent research shows a mix of optimism and caution around AbbVie, with several firms adjusting price targets and ratings as they reassess execution risks, competitive pressures, and the potential impact of the pipeline on valuation.ABBV: Future Returns Will Depend On Immunology Pipeline Clarity And M&A Uncertainty
Analysts have trimmed their price targets for AbbVie by a small amount. This reflects slightly lower revenue growth and P/E assumptions, while also incorporating a modestly higher profit margin and recent mixed research views around competition and pipeline visibility.ABBV: Future Returns Will Hinge On Post-Humira Immunology And Deal Optionality
Analysts have nudged their price target for AbbVie slightly higher to reflect a fair value estimate of about $245 per share, supported by updated assumptions for revenue growth, profit margins, and a modestly lower future P/E. Recent research highlights both increased price targets and more cautious views around competition and the sustainability of outperformance in key immunology drugs.ABBV: Future Returns Will Depend On Post-Humira Immunology And Pipeline Execution
Analysts have trimmed their AbbVie fair value estimate by about $0.10 per share to roughly $244.56. This reflects a mix of slightly higher risk assumptions, modestly adjusted revenue and margin expectations, and a more balanced set of views after recent downgrades and price target changes that suggest outperformance is already well reflected in the current share price.AbbVie's (NYSE:ABBV) Dividend Will Be Increased To $1.73
Jan 08
ABBV: Future Returns Will Hinge On Post-Humira Immunology And Pipeline Execution
Analysts have nudged our AbbVie fair value estimate slightly higher, from $243.55 to $244.68. This reflects modestly stronger long term revenue growth expectations for key immunology franchises and pipeline assets, partially offset by slightly lower margin assumptions and a broadly constructive but mixed backdrop of recent price target revisions and rating changes across the Street.ABBV: Future Performance Will Depend On Extended Exclusivity And Pipeline Execution
Analysts have nudged their average price target on AbbVie modestly higher to reflect a wave of target increases into the mid 240s to low 260s dollar range, supported by stronger visibility into Skyrizi and Rinvoq driven growth, extended Rinvoq exclusivity, and a more favorable large cap biopharma backdrop despite mixed ratings changes. Analyst Commentary Recent research paints a generally constructive picture on AbbVie, with most price target revisions skewing higher even as some firms move to the sidelines.AbbVie (NYSE:ABBV) Is Increasing Its Dividend To $1.73
Dec 02ABBV: Future Performance Will Depend On Pipeline Expansion And Patent Protections
AbbVie’s analyst price target has increased modestly from $241.29 to $243.55. Analysts cite resilient performance in immunology products, extended Rinvoq exclusivity, and improving fundamentals as key drivers of sentiment.AbbVie's (NYSE:ABBV) Dividend Will Be Increased To $1.73
Nov 18ABBV: Future Performance Will Reflect Balance Between Patent Wins and Product Pressures
AbbVie's analyst price target has risen modestly from $237.48 to $241.29. Analysts cite resilient fundamentals and long-term patent settlements, which help offset recent industry downgrades and softer performance in some business units.Continued Expansion in Neuroscience and Immunology Will Drive Leadership Beyond 2025
AbbVie's analyst price target has been raised from approximately $233 to $237 per share. Analysts cite ongoing revenue growth, improved margins, and extended exclusivity for key products as the main drivers behind the upward revision.Expanding Immunology And Neuroscience Will Reshape Global Healthcare
AbbVie's analyst price target has increased significantly, rising from $227 to $233 per share. Analysts cite recent positive developments in patent settlements and stronger-than-expected performance across key growth drivers as the main rationales.Expanding Immunology And Neuroscience Will Reshape Global Healthcare
AbbVie’s consensus price target has been raised from $217.45 to $227.22, as analysts highlight the value added by the extended Rinvoq patent runway, top- and bottom-line beats, pipeline expansion through the Bretisilocin acquisition, and underappreciated royalty streams. Analyst Commentary Bullish analysts cite a substantial extension of Rinvoq’s U.S. patent runway through favorable settlement, delaying generic entry until 2037—4 years beyond prior expectations—and modeling this as adding $11-$24 per share in value.Expanding Immunology And Neuroscience Will Reshape Global Healthcare
AbbVie's price target was raised to $217.45 as analysts cited the value impact of extended Rinvoq exclusivity from litigation settlement, strong Q2 results, and positive pipeline developments, outweighing near-term Aesthetics headwinds. Analyst Commentary Bullish analysts cite the settlement of litigation regarding generic Rinvoq, extending market exclusivity in the U.S. to 2037 and reducing threats from earlier-than-anticipated generic competition.Shareholder Returns
| ABBV | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 5.2% | -2.2% | 0.6% |
| 1Y | 9.3% | 30.4% | 28.7% |
Return vs Industry: ABBV underperformed the US Biotechs industry which returned 30.4% over the past year.
Return vs Market: ABBV underperformed the US Market which returned 28.7% over the past year.
Price Volatility
| ABBV volatility | |
|---|---|
| ABBV Average Weekly Movement | 3.8% |
| Biotechs Industry Average Movement | 10.8% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 3.3% |
Stable Share Price: ABBV has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: ABBV's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 57,000 | Robert Michael | www.abbvie.com |
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox Cosmetic for the treatment of glabellar lines, crow's feet, forehead lines, and platysma bands; Juvederm Collection to treat volume loss in the temples, undereye, cheeks, chin, lips and lower face; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; Qulipta for episodic and chronic migraine; and Vyalev for the treatment of motor fluctuations, as well as Botox Therapeutic to treat chronic migraine, overactive bladder, spasticity, cervical dystonia, and other conditions.
AbbVie Inc. Fundamentals Summary
| ABBV fundamental statistics | |
|---|---|
| Market cap | US$360.63b |
| Earnings (TTM) | US$3.60b |
| Revenue (TTM) | US$62.82b |
Is ABBV overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ABBV income statement (TTM) | |
|---|---|
| Revenue | US$62.82b |
| Cost of Revenue | US$17.57b |
| Gross Profit | US$45.25b |
| Other Expenses | US$41.65b |
| Earnings | US$3.60b |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | 2.03 |
| Gross Margin | 72.03% |
| Net Profit Margin | 5.72% |
| Debt/Equity Ratio | -2,090.3% |
How did ABBV perform over the long term?
See historical performance and comparisonDividends
Does ABBV pay a reliable dividends?
See ABBV dividend history and benchmarks| AbbVie dividend dates | |
|---|---|
| Ex Dividend Date | Apr 15 2026 |
| Dividend Pay Date | May 15 2026 |
| Days until Ex dividend | 16 days |
| Days until Dividend pay date | 14 days |
Does ABBV pay a reliable dividends?
See ABBV dividend history and benchmarksCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/04/30 10:08 |
| End of Day Share Price | 2026/04/30 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
AbbVie Inc. is covered by 51 analysts. 27 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| David Toung | Argus Research Company |
| Emily Field | Barclays |
| Luisa Hector | Berenberg |